BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) and ImmunityBio (NASDAQ:IBRX – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
This table compares BioCryst Pharmaceuticals and ImmunityBio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares BioCryst Pharmaceuticals and ImmunityBio’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$289.68 million||5.60||-$247.12 million||($1.21)||-7.09|
Institutional and Insider Ownership
79.1% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 9.9% of ImmunityBio shares are held by institutional investors. 5.0% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 79.7% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for BioCryst Pharmaceuticals and ImmunityBio, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioCryst Pharmaceuticals currently has a consensus target price of $14.71, suggesting a potential upside of 71.50%. ImmunityBio has a consensus target price of $9.00, suggesting a potential upside of 52.03%. Given BioCryst Pharmaceuticals’ higher possible upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than ImmunityBio.
Volatility and Risk
BioCryst Pharmaceuticals has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
BioCryst Pharmaceuticals beats ImmunityBio on 8 of the 11 factors compared between the two stocks.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.